about
Can we prevent antimicrobial resistance by using antimicrobials better?Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of AmericaHigh-throughput screening of a diversity collection using biodefense category A and B priority pathogensEssential biological processes of an emerging pathogen: DNA replication, transcription, and cell division in Acinetobacter sppPharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions.In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model.Composing compound libraries for hit discovery--rationality-driven preselection or random choice by structural diversity?Architecture and conservation of the bacterial DNA replication machinery, an underexploited drug target.Pangenome and immuno-proteomics analysis of Acinetobacter baumannii strains revealed the core peptide vaccine targets.In vitro and in vivo properties of a fully human IgG1 monoclonal antibody that combats multidrug resistant Pseudomonas aeruginosa.Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy.Novel agents to inhibit microbial virulence and pathogenicity.The antibiotic development pipeline for multidrug‐resistant gram‐negative bacilli: current and future landscapes.Emerging gram-negative infections in burn wounds.Inhaled antibiotics for gram-negative respiratory infections.The enhanced permeability retention effect: a new paradigm for drug targeting in infection.Emerging drugs for nosocomial pneumonia.In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.Fungi treated with small chemicals exhibit increased antimicrobial activity against facultative bacterial and yeast pathogensNew antibiotics for antibiotic-resistant bacteria.The Hyr1 protein from the fungus Candida albicans is a cross kingdom immunotherapeutic target for Acinetobacter bacterial infection.
P2860
Q26829707-5CED2BA2-297F-4953-AE6A-1BE1441420DEQ29616084-419E5BA7-DAAF-49A4-B289-696E28F78042Q30541139-5BBC201A-67AF-4AB2-ABDF-4BF3F08EF33DQ33909111-99251C74-6F42-48AE-9E26-374C81F0E735Q34045418-2C596EA2-BD8A-4EB4-BB60-AC35C137EF16Q35105932-A929C0E3-251C-4D0C-96D6-DAC0AFD6949EQ35532349-2BC44125-7C38-44D2-8900-6100DE0D67A5Q35791501-8C48DEBD-2EF1-481D-96D6-B5CBD9AE4435Q36135237-1D85DA2A-5B92-4F07-809B-F600513F7E39Q36613653-3A888ACC-3574-41E8-BE39-D242B7A08EBCQ37656243-A4781608-BC8A-437A-B909-71E075431743Q37780752-EB6168A7-09F7-4E65-8167-44D04DF6AC28Q37798557-170667B7-4DE6-4537-932F-CB93A14C204FQ37906181-DA67F2EE-1BC7-45A4-A068-46AC86A61C3BQ37937558-08A562AC-595C-41D4-B3D0-26DAF2588DA4Q38051263-D869958C-7B96-460B-B8F7-2CC4A682718FQ38878167-D082F90C-FEF9-481F-991A-8B59081E81B0Q40257051-478E7023-BDB7-40AA-A487-EC532A28CBAEQ42048601-469DF906-FAE9-4AB2-A837-FE81A3FEA7F8Q42183500-C553C653-2D43-4394-85A8-834387D08B87Q54215616-8E74A093-CD2E-4C6F-AB17-C24E7F6A04D6
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
What is in the pipeline for Gram-negative pathogens?
@en
What is in the pipeline for Gram-negative pathogens?
@nl
type
label
What is in the pipeline for Gram-negative pathogens?
@en
What is in the pipeline for Gram-negative pathogens?
@nl
prefLabel
What is in the pipeline for Gram-negative pathogens?
@en
What is in the pipeline for Gram-negative pathogens?
@nl
P2860
P356
P1476
What is in the pipeline for Gram-negative pathogens?
@en
P2093
George H Talbot
P2860
P356
10.1586/14787210.6.1.39
P577
2008-02-01T00:00:00Z